跳转至内容
Merck
所有图片(1)

主要文件

324905

Sigma-Aldrich

Epirubicin Hydrochloride - CAS 56390-09-1 - Calbiochem

A cell-permeable antitumor antibiotic.

别名:

Epirubicin Hydrochloride - CAS 56390-09-1 - Calbiochem, 4ʹ-Epidoxorubicin, HCl

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H29NO11 · xHCl
CAS号:
分子量:
543.52 (free base basis)
MDL编号:
UNSPSC代码:
12352200

质量水平

方案

≥95% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
desiccated (hygroscopic)
protect from light

颜色

orange-red

溶解性

water: 1 mg/mL

运输

ambient

储存温度

2-8°C

InChI

1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1

InChI key

MWWSFMDVAYGXBV-FGBSZODSSA-N

一般描述

A cell-permeable, antitumor antibiotic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.
This product has been discontinued.

生化/生理作用

Cell permeable: yes
Primary Target
Antitumor antibiotic
Product does not compete with ATP.
Reversible: no

警告

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

重悬

Following reconstiution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他说明

Luck, H.J., et al. 1996. Semin. Oncol.23, 33.
Sandri, M.I., et al. 1996. Br. J. Cancer73, 1518.
Boddy, A.V., et al. 1995. Eur. J. Cancer31A, 69.
Pouna, P., et al. 1995. Cancer. Chemother. Pharmacol.35, 257.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Health hazardExclamation mark

警示用语:

Danger

危险分类

Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ramchandra Vigay Amnekar et al.
World journal of gastroenterology, 26(6), 598-613 (2020-02-28)
The prognosis of gastric cancer continues to remain poor, and epigenetic drugs like histone deacetylase inhibitors (HDACi) have been envisaged as potential therapeutic agents. Nevertheless, clinical trials are facing issues with toxicity and efficacy against solid tumors, which may be

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门